IOVA vs CAVA Comparison

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Cava is an emerging fast-casual restaurant chain with $1.2 billion in sales across 439 US company-owned units in 2025. The firm derives most of its revenue from the sale of Mediterranean- and Greek-inspired customizable bowls, salads, pita wraps, and beverages, using an assembly-line format. Cava centrally prepares and manufactures the sauces and dips served in its restaurants and sold in grocery stores. All of Cava's revenue is in the US, with the majority of its footprint in the Southeast and Southwest.